Co-founder of the Institute for Research in Biomedicine (IRB Barcelona) and Chair of its External Advisory Board, Joan Massagué, has been awarded the Spanish National Research Award for 2014, in th
Today the Institute for Research in Biomedicine (IRB Barcelona) has launched an innovative video – featuring its scientists as dancers.
Researchers at the Institute for Research in Biomedicine (IRB Barcelona) have managed to generate a fruit fly (Drosophila melanogaster) model that reproduces human colon cancer.
The award is an important recognition to the project and the research conducted by the team of Iproteos.
GEN - Genetic Engineering and Biotechnology News
The North American journal GEN reports on research performed by Natàlia Carulla, with the Peptides and Proteins Group at IRB, on beta-amyloid aggregates and their relation with Alzheimer’s disease. The study concludes that the most harmful aggregates for neurons are intermediate accumulations of beta-amyloid, these ranging from between 20 and 100 units.
El Mundo Catalunya
IProteos, a spin-off from IRB Barcelona labs and co-funded by the researchers Teresa Tarragó and Ernest Giralt, has received the prize Expoquimia R+D+I for a new drug under development for the treatment of schizophrenia.
The scientific reporter Pere Estupinyà talks to representatives from business, research, political and educational circles to find out whether Catalonia is prepared for a production model based on the generation of knowledge. Estupinyà also visits labs at IRB Barcelona, at the Barcelona Science Park, where he speaks to Joan J Guinovart, director of the centre.
Felice Alessio Bava
ex PhD student in the Translational Control of Cell Cycle and Differentiation Lab
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
Quick facts about IRB
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.
IRB Barcelona is housed within the Barcelona Science Park on the University of Barcelona Pedralbes Campus. It is an integral part of the ‘Bioregion of Catalonia’, a rich landscape of research centres of excellence, universities, science parks, hospitals, scientific infrastructures and pharmaceutical companies, all with a focus on the life sciences. It is a member of the CERCA network of government research centres.